NCT02565849

Brief Summary

The Sickle Cell Anemia (SCA) is a recessive genetic condition, monogenic, resulting in defects in the red cell structure. In the investigators' country, this disease affects about 3,000 children each year and is considered one of the most prevalent disorders among the group of existing hereditary diseases. The lungs are frequently affected in this disease by Acute Chest Syndrome (STA). Besides being the leading cause of death and the second leading cause of hospitalization in SCA, the STA is correlated with cognitive impairment frame these patients, resulting secondary Stroke vaso-occlusion of capillaries that supply the brain tissue. Traditional tests of pulmonary function allow assess whether the person has any commitment in the respiratory system, whether obstructive, restrictive or mixed. To run these tests it is necessary that the patient understands and performs a forced expiratory maneuver to obtain reliable results. In the particular case of SCA, performing these tests it is very difficult due to the presence of cognitive impairment of varying degrees. This results in underdiagnosis of early changes in the lung parenchyma during the therapeutic window, committing the proper monitoring and treatment offered to these patients.

Trial Health

100
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
80

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Feb 2013

Typical duration for all trials

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

February 1, 2013

Completed
2.4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 1, 2015

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

August 1, 2015

Completed
21 days until next milestone

First Submitted

Initial submission to the registry

August 22, 2015

Completed
1 month until next milestone

First Posted

Study publicly available on registry

October 1, 2015

Completed
Last Updated

October 1, 2015

Status Verified

September 1, 2015

Enrollment Period

2.4 years

First QC Date

August 22, 2015

Last Update Submit

September 30, 2015

Conditions

Outcome Measures

Primary Outcomes (18)

  • spirometrics parameters of pulmonary function tests assessed by forced expiratory volume in one second (FEV1)

    1 day

  • spirometrics parameters of pulmonary function tests assessed by forced vital capacity (FVC)

    1 day

  • spirometrics parameters of pulmonary function tests assessed by ratio forced expiratory volume in one second and forced vital capacity (FEV1 / FVC)

    1 day

  • spirometrics parameters of pulmonary function tests assessed by FEF max (Flow Forced Expiratory maximum)

    1 day

  • plethysmographics parameters of pulmonary function tests assessed by Total Lung Capacity (TLC)

    1 day

  • plethysmographics parameters of pulmonary function tests assessed by functional residual capacity (FRC)

    1 day

  • plethysmographics parameters of pulmonary function tests assessed by residual volume (RV)

    1 day

  • plethysmographics parameters of pulmonary function tests assessed by Ratio Residual Volume and Total Lung Capacity (RV / TLC)

    1 day

  • plethysmographics parameters of pulmonary function tests assessed by Airway resistance (Rva)

    1 day

  • diffusion parameters of pulmonary function tests assessed by Diffusing Capacity Carbon monoxide (DLCO)

    1 day

  • diffusion parameters of pulmonary function tests assessed by VA (Volume Alveolar)

    1 day

  • diffusion parameters of pulmonary function tests assessed by diffusion coefficient (DLCO / VA)

    1 day

  • forced oscillation technique assessed by zero resistance at the intercept (R0) in cmH2O/l/s

    1 day

  • forced oscillation technique assessed by resistance at 4 Hz (Rrs4Hz) in cmH2O/l/s

    1 day

  • forced oscillation technique assessed by average resistance (Rm) in cmH2O/l/s

    1 day

  • reactive parameters of the forced oscillation technique assessed by mean reactance (Xm) in cmH2O/l/s is a parameter related to the inhomogeneity of the respiratory system

    1 day

  • reactive parameters of the forced oscillation technique of the respiratory system compliance was measured by dynamic compliance (Crs, dyn) in cmH2O

    1 day

  • reactive parameters of the forced oscillation technique of total mechanical loading of the respiratory system was assessed using the absolute value of the respiratory impedance (Z4Hz) in cmH2O/l/s

    1 day

Study Arms (3)

Control group

Recruited volunteers aged above 18 years with no history of smoking or hospitalization in the last three months without cardiac dysfunction, orthopedic or lung.

Sickle Cell Anemia normal spirometry

Recruited patients aged above 18 years with no history of smoking or hospitalization in the last three months, ability to independent ambulation and spirometry tests and plethysmography with normal medical report.

Sickle Cell Anemia spirometry abnormal

Recruited patients aged above 18 years with no history of smoking or hospitalization in the last three months, ability to independent ambulation and spirometry tests and plethysmography with altered medical report.

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

Patients with sickle cell anemia, type of hemoglobin SS, above 18 years of age, accompanied by the Hematology Clinic at the University Pedro Ernesto hospital and no contraindications for study participation

You may qualify if:

  • Patients older than 18 years
  • Typing of Hemoglobin SS

You may not qualify if:

  • History absence of respiratory infections and hospitalized in the last three months
  • Asthma , smoking, rheumatological and oncological diseases, acute pain and inability to independent ambulation

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Anemia, Sickle Cell

Condition Hierarchy (Ancestors)

Anemia, Hemolytic, CongenitalAnemia, HemolyticAnemiaHematologic DiseasesHemic and Lymphatic DiseasesHemoglobinopathiesGenetic Diseases, InbornCongenital, Hereditary, and Neonatal Diseases and Abnormalities

Study Officials

  • Cirlene Marinho

    University Hospital Pedro Ernesto

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
CROSS SECTIONAL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Study of Ventilatory Mechanics in Patients With Sickle Cell Anemia

Study Record Dates

First Submitted

August 22, 2015

First Posted

October 1, 2015

Study Start

February 1, 2013

Primary Completion

July 1, 2015

Study Completion

August 1, 2015

Last Updated

October 1, 2015

Record last verified: 2015-09